Dainippon Sumitomo Pharma

Healthy bodies, healthy lives

Contact Us Site Map Japanese
HOME
  • News Release
    • Dainippon Sumitomo Pharma
    • Dainippon Pharmaceutical
    • Sumitomo Pharmaceuticals
  • Corporate Information
    • A Message from the Chairman and President
    • Corporate Philosophy
    • Corporate History
    • Corporate Profile
    • Business Units
    • Key Facilities
  • CSR Activities
    • CSR of Dainippon Sumitomo Pharma
    • Mid-term CSR Policy
    • Basic Environmental Policy
    • Basic Safety and Health Policy
    • Compliance Promotion Structure
    • Social Contribution Activities Policy
    • CSR Report
  • Research and Development
    • Discovery Research
    • Research and Development Organization
    • List of Product Development Projects
  • Investor Relations
    • Mid-term Business Plan
    • Financial Information
    • Presentation
    • Annual Report
    • For Shareholders
    • IR Calendar
What's New The What's New Archive
2010.3.11
Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia (PDF43kb)
2010.2.19
Change　of Executive Officers and Merger of Two Subsidiaries in North America (PDF54kb)
2010.2.15
Posted Presentation Material for Analysts Meeting of Second Mid-term Business Plan (Feb.16, 2010)
2010.2.15
Second Mid-term Business Plan(PDF54kb)

  • Terms and Conditions

Dainippon Sumitomo Pharma Co., Ltd.

© Copyright 2005 Dainippon Sumitomo Pharma Co., Ltd. All Rights Reserved.
Internet Explorer 5.x or greater and Netscape Navigator 6.x or greater are recommended for viewing this site.